NLRP3 deficiency accelerates pressure overload-induced cardiac remodeling via increased TLR4 expression

被引:35
作者
Li, Fangfang [1 ,2 ]
Zhang, Hao [1 ,2 ]
Yang, Lu [1 ,2 ]
Yong, Hui [1 ,2 ]
Qin, Qingqing [1 ,2 ]
Tan, Mengtong [1 ,2 ]
Xu, Luhong [1 ,2 ]
Liang, Kai [1 ,2 ]
Zong, Jing [1 ,2 ]
Qian, Wenhao [1 ,2 ]
机构
[1] Xuzhou Med Univ, Affiliated Hosp, Dept Cardiol, 99 Huaihai West Rd, Xuzhou 221000, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Inst Cardiovasc Dis Res, Xuzhou, Jiangsu, Peoples R China
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2018年 / 96卷 / 11期
基金
中国国家自然科学基金;
关键词
NLRP3; Aortic banding; Cardiac remodeling; TLR4; INHIBITION; INFLAMMASOME; HYPERTROPHY; DAMAGE;
D O I
10.1007/s00109-018-1691-0
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
NLRP3, a member of the nucleotide-binding oligomerization domain (NOD)-like receptor family, is involved in cardiac inflammation. However, the functional role of NLRP3 in cardiac remodeling is not clear. To investigate the roles of NLRP3 in pressure overload-induced cardiac remodeling, NLRP3 knockout and wild-type mice were subjected to aortic banding to induce cardiac remodeling. The data showed that NLRP3 expression was downregulated in the remodeling process. NLRP3 deficiency accelerated cardiac hypertrophy, fibrosis, and inflammation responses with deteriorating cardiac dysfunction in the pressure overload-induced cardiac remodeling mouse model. Neonatal rat cardiomyocytes were isolated and stimulated with phenylephrine (PE). We identified NLRP3 as a negative regulator of cardiomyocyte remodeling in PE-stimulated cardiomyocyte remodeling using adenovirus-NLRP3 and NLRP3 siRNA. Mechanistically, we found that the expression of Toll-like receptor (TLR) 4 was upregulated in NLRP3-deficient mouse hearts and PE-stimulated cardiomyocytes. NLRP3 knockout mice subjected to a TLR4 inhibitor revealed a relieved cardiac remodeling response with improved cardiac dysfunction. Our data suggested that NLRP3 could be a therapeutic target for cardiac remodeling and heart failure.Key messagesNLRP3 expression was downregulated in the remodeling process.NLRP3 deficiency accelerated pressure overload-induced cardiac remodeling.NLRP3 acted as a negative regulator of cardiomyocyte remodeling via downregulating TLR4.
引用
收藏
页码:1189 / 1202
页数:14
相关论文
共 25 条
  • [1] Novel Role for Caspase-Activated DNase in the Regulation of Pathological Cardiac Hypertrophy
    Gao, Lu
    Huang, Kun
    Jiang, Ding-Sheng
    Liu, Xiaoxiong
    Huang, Dan
    Li, Hongliang
    Zhang, Xiao-Dong
    Huang, Kai
    [J]. HYPERTENSION, 2015, 65 (04) : 871 - +
  • [2] How cardiomyocytes sense pathophysiological stresses for cardiac remodeling
    Haque, Zaffar K.
    Wang, Da-Zhi
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2017, 74 (06) : 983 - 1000
  • [3] The role of Toll-like receptor 4 (TLR4) in cardiac ischaemic-reperfusion injury, cardioprotection and preconditioning
    Lee, Sam Man
    Hutchinson, Mark
    Saint, David A.
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2016, 43 (09) : 864 - 871
  • [4] Inhibition of myocardial hypertrophy by magnesium isoglycyrrhizinate through the TLR4/NF-κB signaling pathway in mice
    Ma, Donglai
    Zhang, Jianping
    Zhang, Yuanyuan
    Zhang, Xuan
    Han, Xue
    Song, Tao
    Zhang, Ying
    Chu, Li
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 55 : 237 - 244
  • [5] The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation
    Martinez, Gonzalo J.
    Celermajer, David S.
    Patel, Sanjay
    [J]. ATHEROSCLEROSIS, 2018, 269 : 262 - 271
  • [6] Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways
    Mastrocola, Raffaella
    Penna, Claudia
    Tullio, Francesca
    Femmino, Saveria
    Nigro, Debora
    Chiazza, Fausto
    Serpe, Loredana
    Collotta, Debora
    Alloatti, Giuseppe
    Cocco, Mattia
    Bertinaria, Massimo
    Pagliaro, Pasquale
    Aragno, Manuela
    Collino, Massimo
    [J]. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2016, 2016
  • [7] NLRP3 as a potentially novel biomarker for the management of osteoarthritis
    McAllister, M. J.
    Chemaly, M.
    Eakin, A. J.
    Gibson, D. S.
    McGilligan, V. E.
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2018, 26 (05) : 612 - 619
  • [8] Molecular and clinical roles of incretin-based drugs in patients with heart failure
    Orabi, Bassant
    Kaddoura, Rasha
    Omar, Amr S.
    Carr, Cornelia
    Alkhulaifi, Abdulaziz
    [J]. HEART FAILURE REVIEWS, 2018, 23 (03) : 363 - 376
  • [9] Cardiovascular diseases, NLRP3 inflammasome, and western dietary patterns
    Pavillard, Luis E.
    Marin-Aguilar, Fabiola
    Bullon, Pedro
    Cordero, Mario D.
    [J]. PHARMACOLOGICAL RESEARCH, 2018, 131 : 44 - 50
  • [10] NLRP3-inflammasome inhibition prevents high fat and high sugar diets-induced heart damage through autophagy induction
    Pavillard, Luis E.
    Canadas-Lozano, Diego
    Alcocer-Gomez, Elisabet
    Marin-Aguilar, Fabiola
    Pereira, Sheila
    Robertson, Avril A. B.
    Muntane, Jordi
    Ryffel, Bernhard
    Cooper, Matthew A.
    Quiles, Jose L.
    Bullon, Pedro
    Ruiz-Cabello, Jesus
    Cordero, Mario D.
    [J]. ONCOTARGET, 2017, 8 (59) : 99740 - 99756